Grant: Catalyst Grant: Pilot Projects in Aging - Biological & Clinical Aspects of Aging
McMaster University
$50,000.00
Is myostatin blockade an appropriate pharmaceutical strategy for the maintenance of muscle mass in older adults: Lessons from exercise and the muscle stem cell.
EF 2010-11
Résumé
The loss of skeletal muscle mass (sarcopenia) begins in the 5th decade of life and can progress to the point of frailty in the 8th and 9th decade of life and the consequences of age-related sarcopenia can be devastating. The loss in strength associated with sarcopenia leads to an increased incidence of falls and injury among older adults, leading to a loss of independence and, for many, institutionalization. This of course is not to mention the billions of healthcare dollars spent on the treatment of injuries due to falls each year. The blockade of myostatin, a negative regulator of muscle growth, is known to result in a significant gain in muscle mass in animals. Efforts to pharmacologically block myostatin in humans are currently underway for the treatment of diseases such as muscular dystrophy. Whether myostatin blockade is a viable option for increasing muscle mass to reverse human age-related sarcopenia is unknown. We will examine the role of myostatin on human muscle stem cells since muscle stem cell activity is necessary for the growth of skeletal muscle and the dysfunction of these cells is likely a major factor in the progression of sarcopenia. Our lab has recently shown that there is a delay in the activation of muscle stem cells in older adults and we hypothesize this is due to increased myostatin signalling in these cells. We will characterize the interaction of myostatin family members with muscle stem cells before and after exercise. We will also exercise-train older adults and determine whether exercise can alter the relationship between myostatin and muscle stem cells, which may explain the gain in muscle mass following exercise training. These experiments will describe the relationship between myostatin and human muscle stem cells, determine whether exercise training can alter the relationship between myostatin and muscle stem cells, and determine whether myostatin blockade is a potential therapy to counteract age-related sarcopenia.
Programme
Catalyst Grant: Pilot Projects in Aging - Biological & Clinical Aspects of Aging
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
228774
Name
Parise Gianni
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Institute of Aging Pilot Projects
Projecttitle
Is myostatin blockade an appropriate pharmaceutical strategy for the maintenance of muscle mass in older adults: Lessons from exercise and the muscle stem cell.
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Pilot Projects in Aging - Biological & Clinical Aspects of Aging
Keyworddelim
Delayed Stem Cell Activation; Exercise Training; Muscle Hypertrophy; Muscle Stem Cells; Myostatin; Skeletal Muscle Atrophy
Abstract
The loss of skeletal muscle mass (sarcopenia) begins in the 5th decade of life and can progress to the point of frailty in the 8th and 9th decade of life and the consequences of age-related sarcopenia can be devastating. The loss in strength associated with sarcopenia leads to an increased incidence of falls and injury among older adults, leading to a loss of independence and, for many, institutionalization. This of course is not to mention the billions of healthcare dollars spent on the treatment of injuries due to falls each year. The blockade of myostatin, a negative regulator of muscle growth, is known to result in a significant gain in muscle mass in animals. Efforts to pharmacologically block myostatin in humans are currently underway for the treatment of diseases such as muscular dystrophy. Whether myostatin blockade is a viable option for increasing muscle mass to reverse human age-related sarcopenia is unknown. We will examine the role of myostatin on human muscle stem cells since muscle stem cell activity is necessary for the growth of skeletal muscle and the dysfunction of these cells is likely a major factor in the progression of sarcopenia. Our lab has recently shown that there is a delay in the activation of muscle stem cells in older adults and we hypothesize this is due to increased myostatin signalling in these cells. We will characterize the interaction of myostatin family members with muscle stem cells before and after exercise. We will also exercise-train older adults and determine whether exercise can alter the relationship between myostatin and muscle stem cells, which may explain the gain in muscle mass following exercise training. These experiments will describe the relationship between myostatin and human muscle stem cells, determine whether exercise training can alter the relationship between myostatin and muscle stem cells, and determine whether myostatin blockade is a potential therapy to counteract age-related sarcopenia.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
Parise, Gianni
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $37,500~ $0~Institute of Aging~ $12,500~ $0~